Method for Predicting the Risk and Onset Time of Acute Myeloid Leukemia

Background & Unmet Need

• Acute myeloid leukemia (AML) pathogenesis is characterized by the acquisition and accumulation of somatic mutations in certain AML-associated genes
• However, it is not known when these mutations arise, how they evolve, and the relative disease risk conferred by each one
• Unmet Need: Method to identify and stratify mutations correlated to increased AML risk to enable long-term patient monitoring and early therapeutic intervention

Technology Overview

• The Technology: A panel of mutations correlated to increased risk of developing AML for screening and early therapeutic intervention
• Using comprehensive longitudinal genomic studies in AML patients, the inventors identified a panel of high-risk premalignant somatic mutations in certain AML-associated genes
• The detection of these mutations accurately predicts the risk and onset time of AML even years before the emergence of symptoms
• The assay only requires a peripheral blood sample from the individual
• May be used for preventative screening as well as regular monitoring of AML progression in diagnosed patients

Technology Applications

• Assessing the risk of AML in symptom-free individuals for preventative screening purposes
• Predicting AML onset time in symptom-free individuals
• Monitoring AML progression in patients
• Providing guidance to the interventional options for AML patients and highly susceptible individuals

Technology Advantages

• Assessing the risk of AML in symptom-free individuals for preventative screening purposes
• Predicting AML onset time in symptom-free individuals
• Monitoring AML progression in patients
• Providing guidance to the interventional options for AML patients and highly susceptible individuals